Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial

Background: In the phase 3b C-OPTIMISE study (ClinicalTrials.gov, NCT02505542), approximately 80% of patients with early active axial spondyloarthritis (axSpA) remained flare-free from week (W)48 to W96 with full-dose and reduced-dose certolizumab pegol (CZP) after gaining sustained remission (Axial...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2026-06-01
Sarja:	EULAR Rheumatology Open
Linkit:	http://www.sciencedirect.com/science/article/pii/S3050708126000820
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!